论文部分内容阅读
目的:通过谷氨酰胺颗粒对肠易激综合征进行治疗,观察临床治疗效果。方法:统计本院于2014年12月至2016年2月收治的肠易激综合征患者共计88例,根据治疗方式的差异将其平均分为两个组,两组均采用药物治疗,对照组44例患者采用马来酸曲美布丁片进行治疗,观察组44例患者在采用该药物治疗的同时加用谷氨酰胺颗粒进行辅助治疗,对比两组患者的治疗效果。结果:经过相同疗程的治疗之后,对照组44例患者24例显效、13例有效、7例无效,总有效率为84.10%。平均症状消失时间为(4.12±1.95)天。治疗期间7例有复发表现,复发率为15.91%;观察组44例患者28例显效、15例有效、1例无效,总有效率为97.72%。平均症状消失时间为(2.58±1.67)天。治疗期间2例有复发表现,复发率为4.55%。两组患者的总有效率、症状消失天数与复发率之间比值P小于0.05,差异具有统计学意义。结论:对于肠易激综合征患者的临床治疗,采用基本药物治疗的基础上辅以谷氨酰胺颗粒辅助治疗具有着良好的治疗效果,值得临床推广应用。
OBJECTIVE: To treat irritable bowel syndrome (GI) through glutamine granules and observe the clinical effect. Methods: A total of 88 patients with IBS admitted to our hospital from December 2014 to February 2016 were divided into two groups according to the difference of treatment methods. Both groups were treated with drugs and the control group Forty-four patients were treated with trimebutine maleate. Forty-four patients in the observation group received adjuvant therapy with glutamine supplementation, compared with the treatment effect in both groups. Results: After the same course of treatment, 24 cases in the control group were markedly effective, 13 cases were effective, 7 cases were ineffective, the total effective rate was 84.10%. The mean symptom disappearance time was (4.12 ± 1.95) days. The recurrence rate was 15.91% in 7 cases during treatment. In 44 cases in observation group, 28 cases were markedly effective, 15 cases were effective and 1 case was ineffective. The total effective rate was 97.72%. The mean symptom disappearance time was (2.58 ± 1.67) days. Two cases had recurrence during the treatment, the recurrence rate was 4.55%. The total effective rate of two groups of patients, the number of days between symptoms and recurrence rate P was less than 0.05, the difference was statistically significant. Conclusion: The clinical treatment of patients with irritable bowel syndrome, based on the basic drug treatment supplemented with adjuvant treatment with glutamine granules has a good therapeutic effect, it is worthy of clinical promotion and application.